Israel Englander Abeona Therapeutics Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Millennium Management LLC holds 809,966 shares of ABEO stock, worth $5.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

809,966

Previous 2,117,169 61.74%

Holding current value

$5.2 Million

Previous $11.8 Million 67.19%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.76 - $6.02 $6.22 Million - $7.87 Million	-1,307,203 Reduced 61.74%	809,966 $3.86 Million
Q4 2024 Feb 14, 2025	SELL	$5.55 - $6.67 $1.02 Million - $1.23 Million	-184,459 Reduced 8.01%	2,117,169 $11.8 Million
Q3 2024 Nov 14, 2024	SELL	$4.12 - $6.32 $1.55 Million - $2.37 Million	-375,023 Reduced 14.01%	2,301,628 $14.5 Million
Q2 2024 Aug 14, 2024	BUY	$3.17 - $8.05 $2.19 Million - $5.56 Million	690,103 Added 34.74%	2,676,651 $11.3 Million
Q1 2024 May 15, 2024	BUY	$4.07 - $8.68 $2.31 Million - $4.93 Million	567,873 Added 40.03%	1,986,548 $14.4 Million
Q4 2023 Feb 14, 2024	BUY	$3.71 - $5.14 $2.69 Million - $3.73 Million	725,704 Added 104.72%	1,418,675 $7.11 Million
Q2 2023 Aug 14, 2023	BUY	$2.76 - $5.27 $1.42 Million - $2.71 Million	515,016 Added 289.41%	692,971 $2.79 Million
Q1 2023 May 15, 2023	BUY	$2.25 - $3.27 $67,896 - $98,675	30,176 Added 20.42%	177,955 $502,000
Q4 2022 Feb 14, 2023	BUY	$2.4 - $5.65 $354,669 - $834,951	147,779 New	147,779 $455,000

Others Institutions Holding ABEO

# of Institutions

Shares Held

27.8M

Call Options Held

556K

Put Options Held

34.9K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $38.2M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account